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Recombinant rhabdovirus vectors expressing human immunodeficiency virus (HIV) and/or simian immunodeficiency virus (SIV)
proteins have been shown to induce strong immune responses in mice and rhesus macaques. However, the finding that such responses protect
rhesus macaques from AIDS-like disease but not from infection indicates that further improvements for these vectors are needed. Here, we
designed a prime–boost schedule consisting of a rabies virus (RV) vaccine strain and a recombinant vesicular stomatitis virus (VSV) both
expressing HIV Envelope (Env). Mice were primed and boosted with the two vaccine vehicles by different routes and in different
combinations. Mucosal and systemic humoral responses were assessed using enzyme linked immunosorbent assay (ELISA) while the cellular
immune response was determined by an IFN-g ELISPOT assay. We found that an immunization combination of RV and VSV elicited the
highest titers of anti-Env antibodies and the greatest amount of Env-specific IFN-g secreting cells pre- and post-challenge with a recombinant
vaccinia virus expressing HIV89.6 Env. Furthermore, intramuscular immunization did not induce antigen-specific mucosal antibodies while
intranasal inoculation stimulated vector-specific IgA antibodies in vaginal washings and serum. Our results show that it is feasible to elicit
robust cellular and humoral anti-HIV responses using two different live attenuated Rhabdovirus vectors to sequentially prime and boost.
D 2004 Elsevier Inc. All rights reserved.
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Although the Acquired Immunodeficiency Syndrome
(AIDS) and its causative agent, HIV-1, was discovered over
20 years ago, it remains a global health dilemma. In 2003,
the HIV/AIDS pandemic killed approximately 3 million
people and infected approximately 5 million more, raising0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.10.018
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E-mail address: matthias.schnell@jefferson.edu (M.J. Schnell).the number of people currently living with HIV/AIDS to
more than 40 million (AIDS epidemic update, 2003; Joint
United Nations Programme on HIV/AIDS [http://www.
unaids.org]). Numerous candidate vaccine designs and
regimens investigated in rhesus monkeys and humans have
had limited successes in combating HIV, however, insights
from these trials may pave the way for a safe and efficacious
vaccine in the future (McMichael and Hanke, 2003).
HIV poses challenging obstacles in the development of
an efficacious prophylactic or therapeutic vaccine. First,
HIV-1 conceals its conserved receptor and co-receptor
binding sites in heavily glycosylated crevices, which
limits the induction of antibodies against these domains
(Leonard et al., 1990; Robinson, 2002). Second, the weak005) 82–93
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allow the glycoprotein to be shed in various forms during
natural infection. This bviral debrisQ exposes mainly non-
relevant antibody epitopes (McKeating et al., 1991;
Moore et al., 1990). As a result, antibodies are generated
to these envelope subunits that fail to recognize neutral-
izing epitopes present on the mature envelope oligomers
on intact virions (Parren et al., 1999). Third, the ability of
HIV to integrate into the host genome and remain as an
inactive provirus permits it to escape immune surveillance
and thus establish reservoirs in T-cell, macrophage, and
monocyte compartments (Blankson et al., 2002). Lastly,
the error prone HIV reverse transcriptase gives rise to
mutant viruses that can escape both B-cell- (Kwong et al.,
2002) and T-cell-mediated immune responses (McMi-
chael, 1998).
Nonetheless, previous studies have revealed that both
humoral and cellular immune responses play crucial roles in
the immune response against HIV-1 (Ferrantelli et al.,
2002). The humoral immune system is composed of two
distinct effectors: mucosal and systemic antibodies. HIV
predominantly infects via mucosal openings and antibodies
lining these cavities might have an important role for virus
neutralization at the onset of infection. Conversely, once
infection is established, systemic antibodies are important in
the control of viral spread.
Passive transfer of neutralizing monoclonal antibodies
(nmAb) has been shown to protect chimpanzees (Emini et
al., 1992), monkeys (Hofmann-Lehmann et al., 2001;
Mascola et al., 1999, 2000; Parren et al., 2001), and severe
combined immunodeficiency mice populated with human
peripheral blood lymphocytes (hu-PBL-SCID mice) (Parren
et al., 1995; Safrit et al., 1993) from infection with simian-
human immunodeficiency virus (SHIV) or laboratory-
adapted strains of HIV-1. Moreover, human monoclonal
antibodies (mAb) have also been demonstrated to neutralize
laboratory-adapted HIV strains as well as primary HIV
isolates in vitro (Ferrantelli and Ruprecht, 2002).
Additional studies have demonstrated that cellular
immune responses induced by CD8+ cytotoxic T-lympho-
cytes (CTLs) and CD4+ helper T-lymphocytes (HTLs) play
crucial roles in suppressing HIV replication in humans
(Borrow et al., 1994; Greenough et al., 1997; Koup et al.,
1994; Rinaldo et al., 1995; Rowland-Jones et al., 1995) and
SIV infection in macaques (Cranage et al., 1997; Gallimore
et al., 1995; Jin et al., 1999). Despite this, even in the
presence of a robust cellular response, the emergence of
CTL escape mutants in macaques has been observed
(Barouch et al., 2002, 2003) suggesting that activation of
the humoral and cellular immune response is necessary for a
potent HIV vaccine (McMichael and Hanke, 2003; McMi-
chael et al., 2002).
To date, heterologous prime–boost protocols using a
variety of vectors have been tested for their ability to generate
anti-HIV immune responses. These include: naked DNA
(Barouch et al., 2000; Subbramanian et al., 2003; Woodberryet al., 2003), recombinant proteins (Letvin et al., 1997;
Mantis et al., 2001), modified vaccinia Ankara (MVA)
(Amara et al., 2002; Gherardi et al., 2004; Hanke et al.,
2002; McConkey et al., 2003), fowlpox virus (Clements-
Mann et al., 1998; Kent et al., 1998), adenovirus (AdV)
(Buge et al., 1999), influenza virus (Flu) (Gherardi et al.,
2003; Gonzalo et al., 1999; Li et al., 1993), and vesicular
stomatitis virus (VSV) (Haglund et al., 2002; Rose et al.,
2000, 2001). In this study, we assessed the ability of an RV/
VSV protocol to activate mucosal and systemic immune
responses in mice when administered via an intranasal or
intramuscular route.Results
Rhabdoviral boost enhances both humoral and
cell-mediated immunity
We previously demonstrated that RV vectors expressing
HIV-1 Env are able to induce potent and long-lasting anti-
HIV-1 Env cellular responses in mice (McGettigan et al.,
2001). However, current vaccine research in non-human
primate models strongly indicates that even potent cellular
responses are not sufficient to protect from an AIDS-like
disease due to CTL escape mutants (Barouch et al., 2002,
2003). For this reason, strong humoral responses against
HIV-1 gp160 have been suggested as keys to a successful
HIV-1 vaccine. Our previous results demonstrated that anti-
HIV-1 Env humoral responses were detected after priming
with an RV-based vaccine expressing HIV-1 Env, followed
by a boost with recombinant HIV-1 gp120 protein (Schnell
et al., 2000). Here, we analyzed an alternate vaccine strategy
using two different Rhabdoviral vectors expressing HIV-1
Env to prime and boost. For this approach, three groups of
BALB/c mice were immunized intramuscularly with a RV
vector expressing SHIV-189.6P Env ecto and transmembrane
domain fused to the cytoplasmic domain of the RV G (RV-
89.6P). Five weeks after the first immunization, one group
was boosted with the same RV vector while another was
boosted with a heterologous vector, vesicular stomatitis
virus (VSV), expressing HIV-189.6 Env (VSV-89.6). A third
group was not boosted and served as a control (Fig. 1A).
Nine weeks post-prime immunization, all mice were
challenged intraperitoneally with a recombinant vaccinia
virus expressing HIV-189.6 Env (rVV-89.6). Sera from each
mouse were collected as described in Materials and methods
to measure anti-HIV-1 Env antibody response. In addition, 5
days post-challenge spleens were removed to evaluate the
cellular immune response to HIV-1 Env.
Seroconversion to HIV-1 Env and RV G in serum was
analyzed by ELISA and the results are shown in Fig. 2.
Mice that received a single inoculation with RV-89.6P
did not seroconvert to HIV-1 Env before or after rVV-
89.6 challenge (Fig. 2A, Mice A1–A3 and Table 1),
although vector-specific seroconversion was detected
Fig. 1. Prime–boost immunization groups. All mice were primed immunized intramuscularly (A and C) or intranasally (B) and boosted (or not boosted
intramuscularly (A) or intranasally (B and C) 5 weeks post prime.
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with our previous findings that a boost with recombinant
gp120 was necessary to induce seroconversion to HIV-1
Env (Schnell et al., 2000). However, mice that received
two inoculations with RV-89.6P seroconverted to HIV-1
Env after challenge with rVV-89.6 (Fig. 2B, Mice B1-B3
and Table 1) showing that two inoculations with RV is
adequate to prime for seroconversion following rVV-89.6
challenge but did not lead to seroconversion on its own.
Of note, those mice that received a single inoculation
with RV-89.6P, followed by a boost with VSV-89.6
seroconverted to Env at week 8 (3 weeks post-boost) and
elicited consistently high titers of HIV-1 Env-specific
antibodies 5 days post-challenge (Fig. 2C, Mice C1–C3
and Table 1). These results indicate that homologous
boosting increases the HIV-1 Env specific antibody
responses, whereas a heterologous viral vector induces a
more potent humoral response to HIV-1 Env.
After determining that priming and boosting with two
different vectors expressing HIV-1 Env induced the
highest anti-Env antibody titers, we next wanted to
measure the effects of this vaccine regimen on the cellular
response. Although CTL escape mutants were detected in)rhesus macaque studies (Barouch et al., 2002, 2003),
others indicate that strong cellular responses will also be
necessary for an effective HIV-1 vaccine (Kaech et al.,
2002; Seder and Hill, 2000; Yang, 2003). This is based on
the finding that exposed but uninfected individuals have
HIV-1-specific CTLs without detectable antibodies (Row-
land-Jones et al., 1995) and that long-term nonprogressors
are asymptomatic probably due to strong memory CTL
activity (Rinaldo et al., 1995). In addition, there is a
correlation between a strong CTL activity and slow disease
progression (Rinaldo et al., 1995). More importantly, we
wanted to ensure that the strong humoral response detected
above did not interfere with the generation of a robust
cellular response induced by our vaccine vehicle. Five days
post-challenge with rVV-89.6 HIV-1 Env, mice were
sacrificed, spleens removed and the cellular response
determined by IFN-g specific ELISPOT. As shown in Fig.
2D, approximately 2000 splenocytes per million cells were
secreting IFN-g after a single inoculation with RV-89.6P
following a challenge with rVV-89.6. Boosting with the
same vector, RV-89.6P, elicited approximately a 2-fold
increase in spot-forming cells when compared with those
mice that received a single inoculation (Fig. 2E). The
Fig. 2. Three groups of 5 BALB/c mice each were immunized intramuscularly with 3.0  105 ffu of RV-89.6P. Five weeks post-prime inoculation; mice were
not boost (A, D), boosted with 3.0  105 ffu of RV-89.6P (B, E) or boosted 3.0  105 ffu of VSV-89.6 (C, F). ELISAwas used to detect antigen-specific IgG
antibodies in sera on weeks 0, (pre-bleed), 3 (post-prime), 8 (post-boost), and 10 (5 days after challenge with rVV-89.6). Seroconversion to RV-based vaccine is
indicated by RV G antibodies (white bars) at week 8. The four bars of each time period represent the optical density at each reciprocal dilution (100, 300, 900,
and 2700). Four weeks after boost, mice were challenged with rVV-89.6 and 5 days later, the mice were sacrificed and their spleens removed. Single-cell
suspensions were prepared and the ELISPOT assay was used to detect splenocytes that secreted IFN-g after in the presence of the HIV-1 89.6R10 peptide (a
CTL epitope conserved between 89.6 and 89.6P). Data above show three of five mice from each immunization group.
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2.5-fold increase in spot-forming cells when compared with
a single inoculation or homologous boost, respectively (Fig.
2F). Thus, these data demonstrate that the heterologous
prime boost combination of RV and VSV enhances both the
humoral response (Fig. 2C), and significantly increases the
cellular response to HIV-1 Env (Fig. 2F).
Mucosal inoculation induces a systemic response
The above experiment demonstrated that a heterologous
prime–boost regimen augmented both the systemic humoral
and cellular immune response to HIV-1 Env when the
vaccine was administered via an intramuscular route. Often,
the initial contact with HIV-1 occurs in the mucosa due to
sexual contact. Therefore, a potential HIV-1 vaccine might
need to induce a mucosal immune response in addition to a
systemic immune response to provide sterilizing immunity.
While an intramuscular administration of a vaccine is not
likely to induce a mucosal immune response, several studies
have demonstrated immunization through a mucosal routecan elicit both mucosal and systemic immunity (Gherardi et
al., 2003, 2004; Staats et al., 1996).
Previously, a recombinant VSV expressing influenza
virus hemagglutinin administered intranasally was shown
to induce a systemic humoral response that protected
mice from a lethal influenza virus challenge (Roberts et
al., 1998). Others have demonstrated that a mucosal route
of immunization is sufficient to elicit a systemic cellular
immune response (Gherardi et al., 2003). The combina-
tion of a robust mucosal and systemic immune response
could potentially neutralize HIV-1 upon encounter and/or
limit virus propagation in vivo. To evaluate the viability
and effectiveness of a mucosal prime–boost strategy to
elicit both systemic and mucosal immune responses,
BALB/c mice were immunized intranasally with RV-
89.6P. One group was boosted intranasally with RV-89.6P
(homologous) and the second group boosted intranasally
VSV-89.6 (heterologous) 5 weeks after the first immuni-
zation. The last group was not boosted and served as a
control. An additional group was inoculated intranasally
with VSV-89.6 and also served as a control (Fig. 1B). A
Table 1
ELISAwas used to detect antigen (oligomeric gp140)- and vector (RV G)-specific IgG and IgA antibodies both in sera and/or vaginal washings post-challenge
with rVV-89.6 (week 10)
Humoral response Mucosal response
RVG HIV-1 89.6 RVG HIV-1 89.6
S VW S VW
Intramuscular
RV/None z1:900 ND ND ND ND ND
RV/RV N1:2700 1:2700 ND ND ND ND
RV/VSV z1:900 N1:2700 ND ND ND ND
Intranasal
RV/None N1:2700 ND 1:2 1:18 ND ND
RV/RV N1:2700 1:300 1:2 1:54 ND ND
RV/VSV 1:900 N1:2700 1:2 1:6 ND ND
VSV/None ND ND ND ND ND ND
IM/IN
RV/RV 1:2700 ND ND ND ND ND
(S = serum, VW = vaginal washing, and ND = none detected).
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residual disease caused by the vector (two out of five
mice died after immunization with 105 pfu of VSV-89.6).
All groups were challenged intraperitoneally 9 weeks post
prime immunization with rVV-89.6. Serum was collected
via peri-orbital bleeding and vaginal washings were collected
in parallel to measure the induction of a mucosal humoral
response. Spleen were harvested days after challenge withFig. 3. Four groups of 5 BALB/c mice each were immunized intranasally with 4.
prime inoculation; mice were not boost (A and B), boosted with 4.0  105 ffu of R
primed intramuscularly with 3.0  105 ffu of RV-89.6P and 5 weeks later, boosted
antigen-specific IgG antibodies in sera pooled from five mice per group on weeks
with rVV-89.6). Seroconversion to RV-based vaccine is indicated by RV G antibo
optical density at each reciprocal dilution (100, 300, 900, and 2700). Another gro
later, boost intranasally with 4.0  105 ffu of RV-89.6P (E). Four weeks after b
sacrificed and their spleens removed. Single-cell suspensions pooled from two m
splenocytes that secreted IFN-g after in the presence of the HIV-1 89.6R10 peptrVV-89.6 to assess the anti-HIV-1 Env cellular memory
response.
Pooled serum antibodies directed towards oligomeric
HIV-1 Env and RV G were analyzed by ELISA as described
above and the results are shown in Fig. 3. Not surprisingly,
mice that received a single immunization of RV-89.6P did
not seroconvert to Env during the immunization schedule or
post-challenge (Fig. 3A and Table 1), although we detected0  105 ffu of RV-89.6P (A, C and D) or VSV-89.6 (B). Five weeks post-
V-89.6P (C) or boosted 4.0  105 pfu of VSV-89.6 (D). Another group was
intranasally with 4.0  105 ffu of RV-89.6P (E). ELISAwas used to detect
0, (pre-bleed), 3 (post-prime), 8 (post-boost), and 10 (5 days after challenge
dies (white bars) at week 8. The four bars of each time period represent the
up was prime intramuscularly with 3.0  105 ffu of RV-89.6P and 5 weeks
oost, mice were challenged with rVV-89.6 and 5 days later the mice were
ice per group were prepared and the ELISPOT assay was used to detect
ide (F). ELISA and ELISPOT data represent pooled samples.
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bars). These data are in agreement with our previous results
that seroconversion to HIV-1 Env following immunization
with RV-89.6P requires a boost with either a recombinant
gp120 protein (Schnell et al., 2000) or a viral vector
expressing HIV-1 Env (Figs. 2B and C). On the other hand,
we detected a very low response to HIV-1 Env 5 days post-
challenge in mice that received a single immunization with
VSV-89.6 (Fig. 3B). Mice that received two inoculations of
RV-89.6P did not generate the high amount of HIV-1 Env
antibodies (Fig. 3C) as was observed in intramuscularly
immunized mice after challenge (Fig. 2B and Table 1). Mice
that were immunized intranasally with RV-89.6P followed
by a heterologous intranasal boost with VSV-89.6, notably,
seroconverted to Env on week 8 (3 weeks post-boost) and
induced high titers of HIV-1 Env antibodies 5 days after
challenge (Fig. 3D and Table 1).
A benefit of inoculation via the nasal cavity is the
activation of the mucosal immune system, specifically the
production of IgA antibodies. Since the mucosa is the
predominant route of natural HIV-1 infection, it is equally
important to measure the IgA response mounted by potential
vaccines. The above experiments demonstrate that immuni-
zation with two different Rhabdovirus-based vectors admin-
istered intranasally can efficiently induce systemic humoral
immune responses. Next, we assessed if the intranasal
prime–boost regimen, as described above, could elicit HIV-
1 Env specific IgA antibodies in the vaginal mucosa.
A summary of the RV G- and Env-specific IgA ELISA
data are shown in Table 1. Overall, no anti-HIV-1 Env IgA
antibodies were detected in vaginal washings of intranasally
immunized mice. However, there were vector-specific RV
G-IgA antibodies in both vaginal washings and serum in
intranasally inoculated mice that were not observed in
intramuscularly immunized mice (Table 1). These data show
that although intranasal administration of an RV-based
vaccine did not elicit detectable mucosal antibodies directed
against HIV-1 Env, they did induce the production of vector-
specific mucosal antibodies.
Previous results from this lab indicate that BALB/c mice
that received a single immunization of an RV vector
expressing HIV-1 Gag via the intramuscular or intranasal
route produced approximately equivalent cellular responses
as measured by the amount of IFN-g secreting splenocytes
(McGettigan, Tan and Schnell, unpublished data). Presently,
we wanted to evaluate if a mucosal immunization with an
RV vector expressing HIV-1 Env is comparable to an
intramuscular inoculation in inducing systemic cellular
response. Additionally, we also sought to examine whether
an intranasal heterologous immunization scheme using RV
and VSV expressing Env could increase the number of
antigen-specific IFN-g secreting splenocytes.
The systemic cellular memory response to HIV-1 Env was
determined 5 days after challenge with rVV-89.6. Two mice
from each group were sacrificed, and their spleens removed
and pooled. The ELISPOT assay, as described above, wasutilized to assess the amount of Env-specific splenocytes
secreting IFN-g. As shown in Fig. 3F (group A), about 2000
splenocytes secreted IFN-g after a single intranasal inocu-
lation with RV-89.6P while about 6000 splenocytes were
induced after a single intranasal inoculation with VSV-89.6
(Fig. 3F, group B). An intranasal boost using the same RV
vector, RV-89.6P, did not augment the cellular response (Fig.
3F, group C); in contrast to what was observed after an
intramuscular boost using the same RV vector (Fig. 2E). This
is consistent with the lower antibody titer we observed in RV/
RVintranasal (i.n./i.n.) compared to the RV/RVintramuscular
(i.m./i.m.) immunized mice. On the other hand, a heterolo-
gous intranasal boost with VSV-89.6 induced about a 5.5-fold
increase of IFN-g secreting cells over mice immunized once
or twice with the RV vector (Fig. 3F, group D). ELISA and
ELISPOT data from intranasally immunized mice demon-
strate that a homologous boost with the same RV vector, RV-
89.6P, did not significantly increase systemic humoral or
cellular response, unlike what was observed in intramuscu-
larly immunized mice. Nonetheless, these data indicate that a
heterologous prime–boost regimen with RVand VSV is able
to enhance both systemic humoral and cellular responses to
HIV-1 Env when administered intranasally.
Heterologous route of vaccine immunization
Our current data demonstrate that a vaccine regimen
consisting of two different Rhabdovirus vectors to prime and
boost elicited the strongest systemic humoral and cellular
immune responses to Env. We next wanted to evaluate
whether a combination of different routes of administration to
prime and boost could increase the efficiency of the immune
response to Env. We hypothesized that since intramuscular
immunization does not induce a mucosal vector-specific
response, the intranasal inoculation of RV-89.6P could induce
the production of antibodies lining the mucosal cavity.
Therefore, we immunized BALB/c mice intramuscularly
with RV-89.6P followed by an intranasal boost with the same
viral vector 5weeks after prime immunization (Fig. 1C). Nine
weeks post-prime immunization; the mice were challenged
intraperitoneally with rVV-89.6. Sera and vaginal washings
were collected throughout the immunization protocol.
Mice that received an intramuscular prime and intranasal
boost did not seroconvert to Env as shown in Fig. 3E via an
ELISA assay. However, they did produce vector-specific
RVG antibodies on week 8 confirming successful immuniza-
tion with the Rhabdovirus-based vaccine. Anti-Env and anti-
RVG IgA antibodies were not detected in the vaginal
washings throughout the experiment (Table 1). These results
reveal that the heterologous route of vaccine administration
using RV-based vectors expressing HIV-1 Env does not elicit
the production of systemic or mucosal anti-Env antibodies.
To determine the effects of a heterologous route of vaccine
administration on the cellular immune response, we har-
vested the spleens 5 days after challenge with rVV-89.6 and
processed them for an IFN-g ELISPOT. As shown in Fig. 3F,
Table 2
Virus neutralizing activity against HIV-1 (strain MN) of sera from mice immunized as outlined in Fig. 1 were determined five days after rVV-89.6 challenge
Immunization i.m. i.n. Control
VNA RV only RV/RV RV/VSV RV/VSV VSV only WRB
pool
50% b20 b20* 109 24 b20 691
80% b20 b20 47 b20 b20 232
90% b20 b20 28 b20 b20 121
The WRB pool indicates a pool of HIV-1-infected patients.
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RV vector produced approximately 3000 IFN-g secreting
cells. This cellular immune response, however, is not
significantly different from mice that received two immuni-
zations via the same route (Figs. 2E and 3F). Hence, this
experiment indicates that administration of RV-based vac-
cines through theses two different routes does not enhance
systemic humoral or cellular immune responses.
Heterologous prime–boost immunization induce HIV-1
neutralizing antibodies
Lastly, we analyzed if the observed Env-specific anti-
bodies identified in these experiments are associated with
neutralizing activity against HIV-1. For this preliminary
study, the laboratory-adapted HIV-1 strain MN was utilized.
As shown in Table 2, the best neutralizing activity was
observed for pooled sera from mice immunized intra-
muscularly with RV and VSV expressing HIV-1 Env,
whereas the same approach resulted in reduced titers via
the intranasal route. Of note, these results indicate that the
ELISA data for seroconversion correlate well with neutral-
ization activity against a laboratory-adapted HIV-1 strain. It
is interesting to note that a single inoculation with RV or
VSV via any route did not induce any neutralizing activity.Discussion
Results presented here indicate that the use of Rhabdovi-
rus-based vaccines are able to elicit potent immune responses
to HIV-1 Env. We have previously shown that RV vectors
expressing HIV-189.6 Env are capable of eliciting anti-HIV
Env neutralizing antibodies after a recombinant gp120
protein boost (Schnell et al., 2000) and long-lasting cellular
immune responses after a single immunization (McGettigan
et al., 2001). In the present study, we analyzed if it is possible
to enhance these responses by using a live attenuated RV
vector expressing SHIV89.6P Env to prime in conjunction
with another Rhabdovirus, VSV, expressing HIV-189.6 Env.
As described, cellular immune responses to HIV-1 Env were
analyzed by the ELISPOT assay while systemic and mucosal
humoral responses against HIV-1 Env and vector specific
proteins were assessed using ELISA. Expansion of the
cellular response using two distinct live vectors to prime
and boost was initially shown against malaria using Flu andVV (Li et al., 1993). Succeeding studies have shown that
heterologous prime–boost immunization is capable of
expanding the cellular CD8+ T cell response by as much as
30% (Estcourt et al., 2002). Gherardi et al. (2003) and
Gonzalo et al. (1999) have shown that a prime–boost
schedule consisting of Flu and VV or MVA elicited
approximately a 16-fold increase in Env-specific and a 4.5-
fold increase in Gag-specific (Nakaya et al., 2003) IFN-g
secreting splenocytes compared to homologous boosted
mice. Studies using VSV to prime and vaccinia virus (VV)
to boost increased the number of intracellular IFN-g stained
CD8+ T cells by 12-fold when compared to mock boosted
mice. Our results show that a boost with a heterologous vector
(VSV) increases the amount of IFN-g secreting cells by
approximately 2.5- to 5-fold and 4.5- to 5.5-fold higher than
homologously boosted and singly immunized mice, respec-
tively. This is comparable with previous data, which
demonstrates that a second dose of a heterologous vector is
more efficient in expanding the cellular response.
In contrast to the cellular immune response, neutralizing
antibodies against HIV-1 are more difficult to induce (Parren
et al., 1999). Previous studies using VSV expressing
glycoproteins from different serotypes to sequentially prime
and boost was able to augment the anti-Env humoral
responses by 2-fold in comparison to singly immunized mice
(Rose et al., 2000). A similar approach using a combination
of Flu/MVA showed a 4-fold increase in anti-Env antibody
production, in comparison to a Flu/Flu control group
(Gherardi et al., 2003). Both studies show that a heterologous
prime boost approach either through the use of non-cross-
reactive glycoproteins or different viral vectors induced a
more robust immune response to HIV Env. Here, we found
that heterologous (RV/VSV) boosted mice also produced
high titers of HIV-1 specific antibodies as seen for Flu/MVA
and VSV. Of note, to compare different prime–boost
approaches, the experiments have to be performed in parallel.
Homologous boosted (RV/RV) mice immunized intramusc-
ularly also elicited significant amounts of anti-HIV-1 Env 5
days post-challenge, while singly inoculated (RV/None) mice
did not seroconvert to HIV-1 Env during the course of the
experiment. Previous studies have found that SHIV-89.6 and
SHIV-89.6P have highly divergent neutralization epitopes
(Crawford et al., 1999; Etemad-Moghadam et al., 1998;
Montefiori et al., 1998). The absence of a high titer of anti-
Env antibodies at 3 weeks post-boost in homologous boosted
(RV/RV) mice and in single immunized (RV/None) mice
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immunization (89.6P) and in the ELISA (89.6). Nonetheless,
ELISA data from our heterologous regimen indicate that a
combination of RVand VSV may be a better alternative than
using glycoprotein exchange VSV vectors to elicit high titers
of anti-Env antibodies in a Rhabdoviral vaccine regimen.
This is also supported by the finding that only this
combination induced neutralizing antibodies to HIV-1MN.
The mucosal route of vaccine administration is an
important consideration in the development of a prophy-
lactic HIV-1 vaccine regimen. Prior studies have shown that
mucosal vaccine administration can elicit both systemic
humoral and cellular immune responses (Horner et al.,
2001; Lemiale et al., 2003; Mantis et al., 2001; Staats et al.,
1996). Likewise, our data show that intranasal immuniza-
tions can elicit production of both systemic anti-Env IgG
antibodies (humoral) and IFN-g secreting splenocytes
(cellular). Generation of IgA antibodies is a chief criterion
of a mucosal immune response and is ultimately important
at the onset of natural HIV-1 infection. Several groups have
observed production of HIV-1 specific IgA antibodies at
mucosal surfaces after intranasal immunizations with naked
DNA (Horner et al., 2001; Lemiale et al., 2003), Adeno-
virus-type 5 (Ad5) (Lemiale et al., 2003) recombinant gp41
(Mantis et al., 2001) and whole-killed HIV-1 (Dumais et al.,
2002). While we did not observe a detectable level of anti-
HIV-1 Env IgA in vaginal washings or in serum, we did
detect IgA antibodies directed against RV G from intra-
nasally immunized mice. It must be noted, however, that
DNA-based and recombinant protein vaccine protocols
usually consist of multiple boosts, while our regimen
involves a single boost with RV or VSV.
Pre-existing immunity to vaccine vectors is a major
concern when designing candidate vaccines whether it is
generated naturally or artificially. Interestingly, a recent study
found that an intranasal vaccination with an Ad5 expressing
HIV-1 antigens did not overcome prior Ad5 immunity.
Moreover, two intranasal immunizations with Ad5 had lower
anti-HIV cellular and humoral immune response compared to
its intramuscular counterparts (Lemiale et al., 2003). Con-
sistent with this finding, we also observed that two intranasal
immunizations with RV-89.6P had a slightly lower anti-Env
cellular response and no humoral response compared to
intramuscular immunized mice. However, in the presence of
an anti-RV immune response, an intranasal boost with a
different vector, VSV, expressing HIV-1 Env resulted in
enhanced anti-Env cellular and humoral immune response,
comparable to intramuscular (RV/VSV) immunized mice.
In conclusion, prime–boost approaches in HIV vaccine
development consist mainly of DNA-prime and DNA virus
boost regimens. Both have been shown to increase cellular
and humoral responses compared to a single immunization,
however, no approach has yet been able to protect a
monkey model system from SIV/HIV infection (Barouch et
al., 2002, 2003). Ultimately, mass vaccination against small
pox and a high seroprevalence to adenovirus in thepopulation may limit the use of DNA virus-based vaccine
vectors. There are several advantages in using Rhabdoviral
vectors in a prime–boost regimen. On one hand, there is
little seroprevalence to either RV or VSV in the human
population, which makes them excellent candidate vaccine
vectors. Furthermore, pathogenic markers for RV have been
well characterized such as the point mutation at a site in its
glycoprotein that renders recombinant viruses apathogenic
even when introduced intracranially in mice (McGettigan et
al., 2003). Oral administration of RV vaccine strains have
already been shown to be apathogenic in chimpanzees
(World Health Organization, unpublished document W. H.
O./Rab. Res./93.42) while rVSV expressing HIV-1 Env and
SIV Gag protected monkeys from AIDS for up to 14
months post-challenge with SHIV-89.6P (Rose et al.,
2001).
This study indicates that immunization using two
rhabodviral vectors is more potent in inducing the adaptive
immune response to HIV-1 Env when compared to
homologous and non-boosted regimens. Furthermore, our
current protocol highlights the feasibility of using Rhabdo-
virus-based vaccines in a prime–boost regimen.Materials and methods
Viruses
The plasmid encoding the recombinant RV vector
pSBN-333 was previously described (McGettigan et al.,
2003). To construct a recombinant RV expressing the
SHIV89.6P Env ecto-(ED) and transmembrane (TM)
domains fused to the RV glycoprotein (G) cytoplasmic
domain (CD), the SHIV89.6P Env ED and TM were
amplified by PCR from pKB9SHIV(89.6P), (National
Institutes of Health AIDS Research and Reference Reagent
Program [ARRRP]) using Vent polymerase (New England
Biolabs, Inc.) and the primers RP27 5V-GGG CTG CAG
CTC GAG CGT ACG AAA ATG AGA GTG AAG GAG
ATC AGG-3V and RP32 5V-GCC CCG TTA ACT ATA
GAA AGT ACA GCA AAA-3V. The PCR product was
digested with BsiWI–HpaI (New England Biolabs, Inc.)
and was cloned to pBS2H-NL4-3-G which contains the
RV G CD (McKenna et al., 2003). The resulting plasmid
was named pBS289.6P-RVG. To introduce the gene
encoding the chimeric SHIV89.6P Env into pSBN-333,
pBS289.6P-RVG was digested with BsiWI–XbaI and the
2.2-kb fragment cloned into the previously BsiWI–NheI-
digested pSBN-333. The resulting plasmid was designated
pRV-89.6P and the virus RV-89.6P recovered by standard
methods (Schnell et al., 1994).
Recombinant VSVs (rVSV) expressing a chimeric HIV-
189.6 Env fused to the VSV-tail (VSV-89.6) was a kind gift
from John K. Rose (Johnson et al., 1997) (Yale University).
The relative level of HIV-1 Env expression in infected
cells with similar recombinant Rhabdoviral vectors were
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VSV (Haglund et al., 2000; Johnson et al., 1998).
Immunization
Intramuscular: three groups of five 6- to 8-week-old
female BALB/c mice (Harlan Sprague) were primed intra-
muscularly with 3.0  105 foci forming units (ffu) of RV-
89.6P. Five weeks post-prime, one group was boosted
intramuscularly with 3.0  105 ffu of RV-89.6P (homolo-
gous) and another group, with 3.0  105 plaque forming
units (pfu) of VSV-89.6 (heterologous). The third group was
not boosted and served as a control. Intranasal: Four groups
of five 6- to 8-week-old female BALB/c mice were primed
intranasally with either 4.0 105 ffu of RV-89.6P (3 groups)
or 4.0  105 pfu VSV-89.6 (1 group). Five weeks after the
first inoculation, one group (RV-89.6P primed) was boosted
intranasally with 4.0  105 ffu of RV-89.6P (homologous)
while another (RV-89.6P primed) with 4.0  105 pfu of
VSV-89.6 (heterologous). The third group (RV-89.6P
primed) and the VSV-89.6 primed mice were not boosted
and served as controls. Intramuscular/Intranasal: five 6- to 8-
week old female BALB/c mice were primed intramuscularly
with 3.0  105 ffu of RV-89.6P followed by an intranasal
boost with 4.0  105 ffu of RV-89.6P 5 weeks post prime.
All mice were challenged intraperitoneally 9 weeks post
priming with 1.0  107 pfu of VBD3-89.6 obtained from
ARRRP, a recombinant vaccinia virus expressing HIV-189.6
Env (rVV-89.6).
Sample collection
Blood was collected retro-orbitally on weeks 0 (pre-
bleed), 1, 3 (post-prime), 6, 8 (post-boost), and 10 (5 days
after rVV-89.6 challenge). Blood samples were spun at
12,000 rpm for 5 min and serum was collected and stored at
4 8C. Vaginal washings were collected in parallel with blood
samples. A micropipettor was used to flush 65 Al of
phosphate buffered saline (PBS) four to six times into the
vaginal cavity. Vaginal washings were then spun at 10,000
rpm for 15 min to remove cellular debris and supernatants
were collected and stored at 4 8C.
RV G ELISA
RV G protein was purified from sucrose-purified RV
virions as described previously (McGettigan et al., 2003).
RV G was diluted in coating buffer (50 mM Na2CO3, pH
9.6) at a concentration of 200 ng/ml and plated in a 96-
well ELISA Maxisorp plate (Nunc) with 100 Al per well.
Plates were incubated overnight at 4 8C, washed three
times with phosphate buffered saline [PBS]/Tween-20
(PBS [pH 7.4], 0.1% Tween-20) and blocked with block-
ing buffer (PBS [pH 7.4], 5% dry milk powder) for 30 min
at room temperature (RT). Serial dilutions of sera or
vaginal washings were added and plates incubated for 1 hat RT. Plates were washed three times, followed by the
addition of horseradish peroxidase-conjugated goat anti-
mouse IgG (g chain specific, 1:5000) or rat anti-mouse
IgA (a chain specific, 1:2000) (Southern Biotechnology
Associates, Inc). Plates were incubated at 37 8C for 30
min, washed three times and 200 Al of OPD (o-phenyl-
enediamine dihydrochloride; Sigma) substrate was added
to each well. The reaction was stopped with 50 Al of 2M
H2SO4 per well and plates were read at 490 nm.
Oligomeric HIV-189.6 gp140 ELISA
Supernatants from B-SC-1 cells infected with a recombi-
nant vaccinia virus expressing oligomeric HIV-189.6 gp140
(a generous gift from Robert W. Doms, University of
Pennsylvania) (Richardson et al., 1996), were used to coat a
96-well ELISA Maxisorp plate (Nunc). The following steps
of the ELISA were identical to the RV G ELISA protocol
described above.
IFN-c ELISPOT
Five days after challenge with rVV-89.6, mice were
sacrificed, spleens were removed, and single-cell suspensions
were prepared. Red blood cells were removed with ACK
lysing buffer (BioSource), and cells were washed twice in
RPMI-10 supplemented with 10% fetal bovine serum (FBS).
A 96-well multiscreen filtration plate (MAIPS4510, Milli-
pore) was coated overnight at 4 8C with 10 Ag/ml of rat anti-
mouse IFN-g monoclonal antibody (mAb, R4-6A2, Phar-
Mingen) in sterile PBS. The plates were blocked for 1 h with
5% bovine serum albumin (BSA) in PBS at 37 8C. The plates
were prepared for the splenocytes by the addition of 100 Al of
RPMI 1640 supplemented with 10% FBS and incubated for
an additional 2 h. Two-fold dilutions of harvested splenocytes
were plated in triplicate and incubated with or without the
major histocompatibility complex class I-restricted peptide,
89.6R10, (IGPGRAFYAR), which contains a CTL epitope
(for BALB/c mice) from the V3 loop shared between 89.6
and 89.6P Env for 16 h at 37 8C. Plates were washed 10 times
with PBS containing 0.25% Tween-20 and then once with
sterile distilled water. Wells were incubated with 5 Ag/ml of
biotinylated rat anti-mouse IFN-g mAb (XMG1.2, PharMin-
gen) for 2 h and then washed five times with 0.25% Tween 20
in PBS. The wells were treated with 1 mg/ml of horseradish
peroxidase-conjugated streptavidin (Jackson ImmunoRe-
search) in PBS containing 1% BSA, incubated for 2 h at
room temperature, and washed four times. IFN-g-secreting
spot-forming cells were detected by the addition of 3, 3V-
diaminobenzidine and 4-chloro-1-naphthol in cold methanol
(McGettigan et al., 2003).
Virus neutralization
Mouse serum samples were aliquoted into 1.8 ml
cryovials and heat-inactivated for 30 min at 56 8C in a
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RPM for 2 min to pellet cellular debris. Serum was initially
diluted 1:5 in 15% FCS (Gemini) RPMI 1640 media (Quality
Biological) supplemented with 1% l-glutamine (Quality
Biological) and 1% Penicillin/Streptomycin (Quality Bio-
logical) (cRPMI). The initial dilution was followed by serial
4-fold dilutions, ending with 1:5120. As a b+Q control for
neutralization, a well-characterized pool of sera from HIV-1
infected individuals was diluted in a similar manner. Both
HIV-1 negative human sera, diluted 1:5, and cRPMI were
used as negative controls. The dilutions were done in a 96-
well microtiter plate. Twenty-five microliters of each serum
dilution were added to a 500-Al deep-well box. Sample sera
were distributed in replicates of four, whereas control sera
were done in replicates of eight. The T cell line adapted HIV-
1 strain MN was grown and tittered in the human-trans-
formed T-cell line H9 (NIH AIDS Reagent Program).
Twenty-five microliters of MN, diluted to 100–200 TCID50,
was added to each well. The serum sample/virus mixtures
were allowed to incubate for 30 min in a 37 8C/5% CO2
incubator. During this time, H9 cells were prepared for
infection, counted and resuspended at 2  106/ml in fresh
cRPMI. After 30 min, 50 Al of cells were added to each well.
The cultures were incubated overnight in a 37 8C/5% CO2
incubator. On day 1, the cultures were washed three times
(final volume of 500 Al/wash) with cRPMI. The plates were
placed in a centrifuge for 10 min at 1000 RPM (Sorval
Legend RT). After the final wash, 200 Al of cRPMI was
added to each well and mixed with the cell pellets four to five
times. The cells were then transferred to a 96-well round
bottom plate and incubated at 37 8C/5% CO2 for 4 days. On
day 4, 100 Al of supernatant was removed from each well and
lysis solution was added (100 Al of dPBS+ 20 Al of Lysis
Buffer-Coulter Corp.). The plates were stored at 30 8C
until p24 antigen ELISA analysis could be performed. After
thawing the samples and bringing all reagents to room
temperature, the ELISA procedure was performed according
to the manufacturer’s instructions (Coulter Corp.). Repli-
cates of each sample were pooled for use in the assay.
Control wells were also pooled. P24 production for each
sample was measured against baseline viral growth in
cRPMI. Fifty percent, 80%, and 90% neutralization titers
were calculated for each sample (Kim et al., 2003).Acknowledgments
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